5441722026-04-012026-06-305441722026-06-305441722026-04-012026-06-30in-capmkt:OtherExpenses1Member5441722026-04-012026-06-30in-capmkt:ReportableSegments1Member5441722026-04-012026-06-30in-capmkt:ReportableSegments2Member5441722026-04-012026-06-30in-capmkt:ReportableSegments3Member5441722026-04-012026-06-30in-capmkt:ReportableSegments1Member5441722026-04-012026-06-30in-capmkt:ReportableSegments2Member5441722026-04-012026-06-30in-capmkt:ReportableSegments3Member5441722026-04-012026-06-30in-capmkt:ReportableSegments1Member5441722026-06-30in-capmkt:ReportableSegments1Member5441722026-04-012026-06-30in-capmkt:ReportableSegments2Member5441722026-06-30in-capmkt:ReportableSegments2Member5441722026-04-012026-06-30in-capmkt:ReportableSegments3Member5441722026-06-30in-capmkt:ReportableSegments3Member5441722026-04-012026-06-30in-capmkt:ReportableSegments1Member5441722026-06-30in-capmkt:ReportableSegments1Member5441722026-04-012026-06-30in-capmkt:ReportableSegments2Member5441722026-06-30in-capmkt:ReportableSegments2Member5441722026-04-012026-06-30in-capmkt:ReportableSegments3Member5441722026-06-30in-capmkt:ReportableSegments3Member5441722026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15441722026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss25441722026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544172INDGNNOTLISTEDINE065X01017Indegene LimitedMain BoardEquity2026-04-012027-03-312026-07-302026-07-10INRMillionsQuarterlyFirst quarterMulti segment2026-07-3017:30:002026-07-3018:15:00Declaration of unmodified opinion2026-04-012026-06-30UnauditedConsolidated106310000002900000001092100000000065910000006400000044100000022980000009394000000152700000001527000000293000000720000003650000000116200000000001162000000118000000128000000011620000000118000000048100000024.844.81004.844.81Earnings per share is not annualised for quarter ended <br /> <br /> Notes forming part of the results Amount in INR million except per share data and where otherwise stated <br /> <br /> 1 The above Consolidated Financial Results of Indegene Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret symbol in the financial information denote for amounts less than INR 5 lakhs <br /> <br /> 2 The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 July 2026 and approved by the Board of Directors at its meeting held on 30 July 2026 The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year upto 31 March 2026 and published unaudited year to date figures upto 31 December 2025 being the end of the third quarter of the previous financial year which were subject to limited review <br /> <br /> 3 The Consolidated Financial Results for the quarter and year ended 31 March 2026 are available on the National Stock Exchange of India Limited URL wwwnseindiacom the BSE Limited website URL wwwbseindiacom and on the Companys website URL wwwindegenecom investorrelations <br /> <br /> 4 IPO Fund Utilisation <br /> During the year ended 31 March 2025 the Company had completed Initial Public Offer IPO of 40766550 equity shares of face value of INR 2 each at an issue price of INR452 per share Issue price of INR 422 per share including a share premium of INR 420 per share for employee quota towards fresh issue comprising fresh issue of 16833818 shares aggregating to INR 7600 and offer for sale of 23932732 shares by selling shareholders aggregating to INR 10818 The equity shares of the Company are listed in National Stock Exchange of India Limited NSE and BSE Limited BSE on 13 May 2024 The Company has received an amount of INR 7246 net of Company s share of IPO expenses of INR 354 retained in the Public Offer Account to the extent unpaid from the proceeds of the fresh issue Out of the Company s shares of IPO expenses INR 319 has been adjusted to securities premium <br /> <br /> The utilization of IPO proceeds of INR 7246 is summarized as below <br /> Repayment or prepayment of indebtedness of one of the material Subsidiary ILSL Holdings Inc The amount to be utilised as per the offer document is 3950 The amount utilized up to 30 June 2026 is 3950 The amount unutilized as of 30 June 2026 is nil <br /> Funding the capital expenditure requirements of the Company and one of our material subsidiaries Indegene Inc The amount to be utilised as per the offer document is 644 The amount utilized up to 30 June 2026 is 644 The amount unutilized as of 30 June 2026 is nil <br /> Technology cybersecurity and cloud infrastructure related cost The amount to be utilised as per the offer document is 350 The amount utilized up to 30 June is 350 The amount unutilized as of 30 June 2026 is nil <br /> General corporate purposes and inorganic growth The amount to be utilised as per the offer document is 2302 The amount utilized up to 30 June 2026 is 2302 The amount unutilized as of 30 June 2026 is nil <br /> The total amount to be utilised as per the offer document is 7246 The total amount utilized up to 30 June 2026 is 7246 The total amount unutilized as of 30 June 2026 is nil <br /> <br /> 1 Pursuant to the Special Resolution passed at the Shareholders Meeting held on 12 August 2025 the Company has revised the objects as per offer document As per the revised objects an amount of INR 37 is adjusted from funding capital expenditure requirements towards repayment of indebtedness of ILSL Holdings Inc for the difference arising due to exchange rate fluctuation as on the date of offer document and as on the date of repayment Further an amount of INR 350 is reclassified from funding capital expenditure requirement towards utilization for services including cloud infrastructure and security services productivity tools cybersecurity and support services availed by the Company and Indegene Inc Further the Board of Directors of the Company has approved the transfer of unutilized IPO expense towards funding capital expenditure requirement by way of Board Resolution passed on 29 January 2026 The unutilized amount of INR 2 has been transferred to the net IPO proceeds thereby increasing it from INR 7244 to INR 7246 and earmarked for funding capital expenditure requirements at the Company s office premises <br /> <br /> 2 During the year ended 31 March 2025 the Company has repaid loan of USD 47 million and 200 thousands or INR 3950 outstanding in the books of ILSL Holdings Inc material subsidiary in line with Object 1 of the offer document The amount of INR 37 utilised over and above the maximum amount specified as per the original amount as per offer document of INR 3913 was due to exchange rate fluctuation as on the date of offer document and as on the date of payment The Special Resolution passed on 12 August 2025 revises the object amount to adjust this difference <br /> <br /> Out of the net proceeds there are no amounts that are unutilised as of 30 June 2026 <br /> <br /> 6 Exception Item Litigation Expenses <br /> During the year 2020 21 Indegene Inc a subsidiary of the Company was named in a class action lawsuit filed in the US District Court of New Jersey alleging non compliance with the Telephone Consumer Protection Act of 1991 TCPA by sending unsolicited fax advertisements without the recipient s prior express invitation or permission <br /> Plaintiff initiated this matter through the filing of its Class Action Complaint against Indegene Inc Indegene Encima Inc Indegene Wincere Inc and Indegene Healthcare LLC collectively Indegene or Defendants seeking the Court to award actual monetary loss from the alleged TCPA violations in an amount to be proven in Court or the sum of USD 500 for each violation whichever is greater and that the Court award treble damages of USD 1500 if the violations are deemed wilful or knowing Additionally the Plaintiff seeks the Court award pre judgment interest and costs to be determined upon presentation of suitable evidentiary support <br /> During the year ended 31 March 2026 the matter progressed to mediation and the Group agreed in principle to a mediator proposed settlement framework providing for a maximum settlement amount of INR 417 or USD 4 million and 720 thousands The proposed settlement is structured as a claims made arrangement whereby the actual outflow is contingent upon valid claims submitted by eligible class members and unclaimed amounts if any revert to the Group The proposed settlement remains subject to execution of definitive agreements and approval by the Court <br /> Based on the status of the proceedings and Groups assessment supported by external legal advice the Group during the year ended 31 March 2026 concluded that a present obligation exists and that an outflow of economic resources was probable which could be reliably estimated Accordingly the Group recognised a provision of INR 203 or USD 2 million and 300 thousands including estimated legal costs representing best estimate of the expenditure required to settle the obligation which has been disclosed as an exceptional item in the results for the quarter and year ended 31 March 2026 and the Group does not estimate any change in the amount of provision as on 30 June 2026 The term sheet for the settlement agreement dated 25 May 2026 has been duly signed which will be formalizing into the Settlement agreement post approval by the court <br /> <br /> 7 The Board of Directors in its meeting on 29 April 2026 have proposed a final dividend of INR 2 and 25 paise per equity share for the financial year ended 31 March 2026 The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved would result in a cash outflow of approximately INR 542Other Expenses2298000000Enterprise Medical Solutions2736000000Enterprise Commercial Solutions7502000000Others39300000010631000000010631000000Enterprise Medical Solutions716000000Enterprise Commercial Solutions1197000000Others-1150000001798000000640000002070000001527000000Enterprise Medical Solutions0Enterprise Commercial Solutions0Others0000Enterprise Medical Solutions0Enterprise Commercial Solutions0Others00005 Notes on segment reporting <br /> <br /> During the year ended 31 March 2026 the Group effective 01 October 2025 has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the chief operating decision maker reviews and evaluates performance of the business of the Group Pursuant to the above in accordance with the requirement specified in Ind AS 108 the comparative period information has been recasted to give the effect of this change <br /> <br /> As a consequence the Group currently has 2 reportable segment ie Enterprise Commercial Solutions and Enterprise Medical Solutions <br /> <br /> Operating segments are identified as components of an enterprise for which discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance The Groups chief operating decision maker is the Chief Executive Officer and Executive Director <br /> <br /> Assets and liabilities used in the Groups business are not identified to any of the operating segments as these are used interchangeably between segments Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous <br /> <br /> Others mainly comprises of consultancy and clinical business. <br /> <br /> Other unallocable expenditure net of unallocable income for the three months ended 30 Jun 2026 includes depreciation and amortisation expense INR 441 and unallocable expenses INR 52 net of other income INR 286Remeasurement of defined benefit obligation-29000000-29000000-7000000Exchange differences on translating the financial statements of foreign operations97000000Net change in fair value of forward contracts designated as cash flow hedges5800000015500000015000000118000000UnauditedtrueDeloitte Haskins & Sellstrue2028-04-30